New drug cocktail aims to tackle rare lymphoma
NCT ID NCT06504940
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a drug called orelabrutinib combined with chemotherapy (bendamustine and rituximab or obinutuzumab) in people newly diagnosed with marginal zone lymphoma, a rare blood cancer. The treatment is given in cycles, followed by a maintenance phase with orelabrutinib alone. The goal is to see if this combination improves complete response rates and is safe. The trial is recruiting 69 participants across two age-based groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Orelabrutinib combined with bendamustine and rituximab or obinutuzumab
- What this could lead to
- If successful, this could offer a new first-line treatment option for marginal zone lymphoma, potentially improving complete response rates and delaying disease progression.
- What could go wrong
- This is an early-phase (phase 2) study with a small number of participants (69). The combination may cause side effects like low blood counts or infections, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital ，Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Smartwatches track hidden heart risk in blood cancer patients
- New drug combo aims to tackle Hard-to-Treat lymphoma